<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03312361</url>
  </required_header>
  <id_info>
    <org_study_id>1000051539</org_study_id>
    <nct_id>NCT03312361</nct_id>
  </id_info>
  <brief_title>Assessing Air Travel Safety in Neuromuscular Dystrophy: Standard Versus Prolonged High Altitude Simulation Tests</brief_title>
  <official_title>Assessing Air Travel Safety in Neuromuscular Dystrophy: Standard Versus Prolonged High Altitude Simulation Tests</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if a prolonged high altitude simulation test (HAST) lasting two hours,
      identifies more patients at risk of respiratory failure than the standard HAST lasting 20
      minutes, in patients with neuromuscular disease (NMD) and severe pulmonary restriction. To
      evaluate the safety of supplemental oxygen administered in those with a positive HAST in the
      NMD population.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 6, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prolonged high altitude simulation test</measure>
    <time_frame>3 years</time_frame>
    <description>To determine if a prolonged high altitude simulation test (HAST) lasting two hours, identifies more patients at risk of respiratory failure than the standard HAST lasting 20 minutes, in patients with NMD and severe pulmonary restriction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interventional high altitude simulation test</measure>
    <time_frame>3 years</time_frame>
    <description>In patients with a positive standard or prolonged HAST, we will evaluate the safety of supplemental oxygen administered during a HAST for this population</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Neuromuscular Diseases</condition>
  <condition>High Altitude Hypoxia</condition>
  <arm_group>
    <arm_group_label>15% Oxygen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will breath in 15% oxygen for 2 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>15% oxygen</intervention_name>
    <description>Participants will inhale 15% oxygen for 2 hours to see how it affects them.</description>
    <arm_group_label>15% Oxygen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  individuals with a confirmed diagnosis of NMD

          -  age ≥ 5 years of age

          -  absence of hypoxia at rest, defined as oxygen saturation ≥ 92% for two consecutive
             minutes while at rest and breathing room air

          -  absence of daytime hypercapnea at rest, defined by partial pressure of carbon dioxide
             (pCO2) less than 45 mmHg on capillary or arterial blood gas at rest

          -  patient or authorized substitute decision maker provides consent to study
             participation.

        Exclusion Criteria:

          -  current respiratory tract infection

          -  inability to comply with the study procedures

          -  severe heart failure as defined by uncontrolled symptoms of heart failure, or left
             ventricular ejection fraction &lt; 30%

          -  presence of a tracheostomy

          -  use of domiciliary bilevel positive airway pressure (BPAP) for more than 12 hours
             daily

          -  recent hospital admission within the past 4 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 12, 2017</study_first_submitted>
  <study_first_submitted_qc>October 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2017</study_first_posted>
  <last_update_submitted>April 22, 2019</last_update_submitted>
  <last_update_submitted_qc>April 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Reshma Amin</investigator_full_name>
    <investigator_title>Respirologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Altitude Sickness</mesh_term>
    <mesh_term>Neuromuscular Diseases</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

